Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
Revvity (RVTY) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago.
Revvity to Report Q1 Earnings: What's in Store for the Stock?
RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data
Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost collaboration in biologics development.
Revvity Gains on Diagnostics Strength, Faces China Headwinds
RVTY gains from strong diagnostics and software growth, but China weakness, soft demand, and margin pressures temper its near-term outlook.
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Why Is Revvity (RVTY) Down 5.1% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY gains from strong diagnostics demand and fast-growing Signals software, but China policy pressure and weak research spending temper near-term growth.
Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Revvity: Close To A Buy, Not Quite There
Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.
Here's Why Revvity (RVTY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
RVTY stock climbs after Q4 adjusted EPS of $1.70 top estimates with revenue improving 5.9% to $772.1 million.
